Skip to main content

Table 2 Reported outcomes and follow up periods

From: Long-term prognosis of chronic total occlusion treated by successful percutaneous coronary intervention in patients with or without diabetes mellitus: a systematic review and meta-analysis

Studies

Follow-up periods

Clinical outcomes

Liu et al

36 ± 12 months

Cardiac death, AMI, TLR, MACE

Claessen et al

5 years

All-cause mortality, MI, TVR, CABG, MACE

Sohrabi et al

12 months

Cardiac death, Non-cardiac death, MI, TVR, MACE

Ruiz-Garcia

12 months

Death, TVR, AMI, stent thrombosis, stroke, MACE

Rha et al

12 months

Total death, cardiac death, MI, TLR, TVR, TLR-MACE, TVR-MACEs, Total MACE

Yang et al

13.5 ± 4.1 months

All-cause death, cardiac death, MI, stroke, repeat revascularization, MACCE

Sanguineti et al

4.2 (2.5–6.6) years

All-cause mortality, cardiac death, TLR, Total TVR, CABG, MI, MACE

Tsai et al

5 (1–10) years

All-cause mortality, cardiovascular mortality, MI, MACE

Guo et al

2.6 (1.2–4.7) years

Cardiac mortality, MI, TVR, and MACE

Yan et al

42(24–78.25) months

All-cause death, cardiac death, MI, repeat revascularization, TVR

Flores-Umanzor et al

4.03 (2.6–4.8) years

All-cause death, cardiac death, AMI, PCI-of non-CTO vessel, heart failure hospitalization

  1. AMI acute myocardial infarction, TLR target lesion revascularization, MACE major adverse cardiac events, TVR target vessel revascularization, CABG coronary artery bypass grafting, MACCE major adverse cardiac and cerebrovascular events, PCI percutaneous coronary intervention, CTO chronic total occlusion